Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian-Reference-Cited by-同舟云学术

Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian

Published:2018-06-14 Issue:3 Volume:89 Page:280-296
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Grossmann Mathis¹²^ORCID,Ramchand Sabashini K.¹²,Milat Frances³⁴⁵,Vincent Amanda³⁶,Lim Elgene⁷⁸,Kotowicz Mark A.⁹¹⁰¹¹,Hicks Jill¹²,Teede Helena³⁶^ORCID

Affiliation:

1. Department of Endocrinology; Austin Health; Heidelberg Vic. Australia

2. Department of Medicine; Austin Health; The University of Melbourne; Heidelberg Vic. Australia

3. Department of Endocrinology; Monash Health; Clayton Vic. Australia

4. Hudson Institute of Medical Research; Clayton Vic. Australia

5. Department of Medicine; School of Clinical Sciences; Monash University; Clayton Vic. Australia

6. Monash Centre for Health Research and Implementation; Monash Public Health and Preventative Medicine; Monash University; Clayton Vic. Australia

7. Garvan Institute of Medical Research; Darlinghurst NSW Australia

8. St Vincent's Hospital; University of New South Wales Sydney; Darlinghurst NSW Australia

9. Deakin University; Geelong Vic. Australia

10. Department of Endocrinology and Diabetes; University Hospital; Geelong Vic. Australia

11. Department of Medicine; Melbourne Medical School - Western Campus; The University of Melbourne; St Albans Vic. Australia

12. Breast Cancer Network Australia; Camberwell Vic. Australia

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cen.13735/fullpdf

Reference75 articles.

1. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17;Goss;J Natl Cancer Inst,2005

2. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials;Dowsett;Lancet,2015

3. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer;Pagani;N Engl J Med,2014

4. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials;Saha;J Clin Oncol,2017

5. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial;Davies;Lancet,2013

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine consequences of breast cancer therapy and survivorship;Climacteric;2024-06-12

2. Cancer survivorship and bone health;The Lancet Healthy Longevity;2024-03

3. A multidimensional assessment of payback: Evaluating the impact of Breast Cancer Trials;Asia-Pacific Journal of Clinical Oncology;2024-01-04

4. Effect of Combining Impact-Aerobic and Strength Exercise, and Dietary Habits on Body Composition in Breast Cancer Survivors Treated with Aromatase Inhibitors;International Journal of Environmental Research and Public Health;2023-03-10

5. Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials;Metabolism;2022-03